|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Gastrointestinal neuroendocrine tumors treated with high dose octreotide-LAR:A systematic literature review显示文摘AIM:To review literature on efficacy and safety of octreotide-long-acting repeatable(LAR)used at doses higher than the Food and Drug Administration(FDA)-approved 30 mg/mo for treatment of neuroendocrine tumors(NETs).METHODS:We searched Pub Med and Cochrane Library from 1998-2012,5 conferences(American Society of Clinical Oncology,Endocrine Society,European Neuroendocrine Tumor Society,European Society for Medical Oncology,North American Neuroendocrine Tumor Society)from 2000-2013 using Me SH and keyterms including neuroendocrine tumors,carcinoid tumor,carcinoma,neuroendocrine,and octreotide.Bibliographies of accepted articles were also searched.Two reviewers reviewed titles,abstracts,and full-length articles.Studies that reported data on efficacy and safety of≥30 mg/mo octreotide-LAR for NETs in human subjects,published in any language were included in the review.RESULTS:The search identified 1086 publications,of which 238 underwent full-text review(20 were translated into English);17 were included in the review.Studies varied in designs,subjects,octreotide-LAR regimens,and definition of outcomes.Eleven studies reported use of higher doses to control symptoms and tumor progression,although symptom severity and formal quality-of-life analysis were not quantitatively measured.Ten studies reported efficacy,describing 260 subjects with doses ranging from 40 mg/mo or 30 mg/3 wk up to 120 mg/mo.Eight studies reported expert clinical opinion that supported dose escalation of octreotide-LAR up to 60 mg/mo for symptom control and suggested increased doses may be effective at preventing tumor progression.Eight studies reported safety;there was no evidence of increased toxicity associated with doses of octreotide-LAR>30 mg/mo.CONCLUSION:As reported in this review,octreotide-LAR at doses>30 mg/mo is being prescribed for symptom and tumor control in NET patients.Furthermore,expert clinical opinion provided support for escalation of somatostatin analogs for refractory hormonal symptoms. | Michael S Broder David Beenhouwer Jonathan R Strosberg Maureen P Neary Dasha Cherepanov | 2015 | World Journal of Gastroenterology2015，21，6： | 8 |
| 2 | Appropriateness of systemic treatments in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors显示文摘AIM:To evaluate systemic treatment choices in unresectable metastatic well-differentiated pancreatic neuroendocrine tumors(PNETs)and provide consensus treatment recommendations.METHODS:Systemic treatment options for pancreatic neuroendocrine tumors have expanded in recent years to include somatostatin analogs,angiogenesis inhibitors,inhibitors of mammalian target of rapamycinand cytotoxic agents.At this time,there is little data to guide treatment selection and sequence.We therefore assembled a panel of expert physicians to evaluate systemic treatment choices and provide consensus treatment recommendations.Treatment appropriateness ratings were collected using the RAND/UCLA modified Delphi process.After studying the literature,a multidisciplinary panel of 10 physicians assessed the appropriateness of various medical treatment scenarios on a 1-9 scale.Ratings were done both before and after an extended discussion of the evidence.Quantitative measurements of agreement were made and consensus statements developed from the second round ratings.RESULTS:Specialties represented were medical and surgical oncology,interventional radiology,and gastroenterology.Panelists had practiced for a mean of15.5 years(range:6-33).Among 202 rated scenarios,disagreement decreased from 13.2%(26 scenarios)before the face-to-face discussion of evidence to 1%(2)after.In the final ratings,46.5%(94 scenarios)were rated inappropriate,21.8%(44)were uncertain,and30.7%(62)were appropriate.Consensus statements from the scenarios included:(1)it is appropriate to use somatostatin analogs as first line therapy in patients with hormonally functional tumors and may be appropriate in patients who are asymptomatic;(2)it is appropriate to use everolimus,sunitinib,or cytotoxic chemotherapy therapy as first line therapy in patients with symptomatic or progressive tumors;and(3)beyond first line,these same agents can be used.In patients with uncontrolled secretory symptoms,octreotide LAR doses can be titrated up to 60 mg every4 wk or up to 40 mg every 3 or 4 wk.CONCLUSION:Using the Delphi process allowed physician experts to systematically obtain a consensus on the appropriateness of a variety of medical therapies in patients with PNETs. | Jonathan R Strosberg George A Fisher Al B Benson Lowell B Anthony Bulent Arslan John F Gibbs Edward Greeno Renuka V Iyer Michelle K Kim William J Maples Philip A Philip Edward M Wolin Dasha Cherepanov Michael S Broder | 2015 | World Journal of Gastroenterology2015，21，8： | 2 |
| 3 | Chitosan-A versatile semi-synthetic polymer in biomedical applications 显示文摘 | Dasha M Chiellinia F Ottenbriteb R M | 2011 | Progress in Polymer Science2011，36，： | 1 |
| 4 | Chitosan-A versatile semi-synthetic polymer in biomedical applications显示文摘 | Dasha M Chiellini F Ottenbriteb R M | 2011 | Progress in PolymerScience2011，36，： | 1 |
| 5 | Orientationdependent mechanical properties of commercially pure(cp)titanium显示文摘 | PANDA S SAHOOA S K DASHA A | 2014 | Materials Characterization2014，，： | 1 |
| 6 | Chitosan-aversatile semi-synthetic polymer in biomedical applications显示文摘 | Dasha M Chiellini F Ottenbriteb R M | 2011 | Progress in Polymer Science2011，36，： | 1 |
| 7 | Chemical composition and antioxidant activity of ultrasoundassisted extract of the endemic plant Haberlea rhodopensis Friv显示文摘 | Dasha Mihaylova Mirena Ivanova Slava Bahchevanska | 2015 | J Food Sci Technol2015，52，4： | 1 |
| 8 | Chitosan-aversatile semi-synthetic polymer inbiomedical applications显示文摘 | DASHA M CHIELLINI F OTTENBRITEB M | 2011 | Prog Polym Sci2011，36，： | 1 |
| 9 | Healthcare and economic impact of diarrhea in patientswith carcinoid syndrome显示文摘AIM To examine healthcare resource utilizationpatterns and costs accrued by carcinoid syndrome (CS)patients with and without diarrhea.METHODS: We conducted a retrospective cohort studyusing MarketScan data from 1/1/2002-12/31/2012.Newly diagnosed CS patients had 1 medical claim forCS (ICD-9-CM code 259.2) plus either ≥ 1 additionalclaim for CS or for carcinoid tumors (ICD-9-CM 209.x), and had no evidence of CS for 1 year prior to index CS diagnosis, in commercially-insured patients 〈 65years old. Patients were required to have continuousenrollment one year prior and after index date (firstclaim with CS diagnosis in the ID period). We identifiedpatients with evidence of non-infectious diarrhea (ICD-9-CM codes 564.5 and 787.91) within one year from theindex date. Overall and CS-related healthcare resourceutilization and costs were compared between patientswith and without non-infectious diarrhea during theone year period after the index date.RESULTS: There were 2822 newly diagnosed CSpatients; 534 (18.9%) had evidence of non-infectiousdiarrhea. Compared to patients without non-infectiousdiarrhea, non-infectious diarrhea patients morecommonly had at ≥ 1 CS-related hospitalization(13.7% vs 7.2%), ≥ 1 CS-related ED visit (11.0% vs4.4%), and CS-related office visits in one year (6.9 vs4.1; all p 〈 0.001). After adjusting for demographics,region, number of chronic conditions and the CharlsonComorbidity Index, the proportions of patients withany and with CS-related hospitalizations were 9.7%and 6.8% higher, respectively, among non-infectiousdiarrhea patients compared to those with without noninfectiousdiarrhea (p 〈 0.001). Unadjusted costs weresignificantly higher among non-infectious diarrheapatients vs those without non-infectious diarrhea. Thenon-infectious diarrhea group was also more costly,with adjusted mean annual costs of $81610, comparedto $51719 in the group without non-infectious diarrhea(p 〈 0.001).CONCLUSION: Diarrhea is burdensome and costlyin CS patients. Reduction of CS-related healthcareexpenditures may be achievable through preventivetreatment and appropriate management of diarrhea inCS. | Michael S Broder Eunice Chang Dorothy Romanus Dasha Cherepanov Maureen P Neary | 2016 | World Journal of Gastroenterology2016，22，6： | 1 |
| 10 | Gut feelings and the reaction to perceived inequity: The interplay between bodily responses, regulation, and perception shapes the rejection of unfair offers on the ultimatum game显示文摘 | Barnaby Dunn Davy Evans Dasha Makarova Josh White Luke Clark | 2012 | Cognitive Affective & Behavioral Neuroscience2012，，3： | 1 |
| 11 | Natural protective glue protein,sericin bioengineered by silkworms:potential for biomedical and biotechnological applications显示文摘 | Kundua S C Dasha B C Dasha R | 2008 | Prog Polym Sci2008，33，10： | 1 |
| 12 | Healthcare utilization and costs in children with stable and uncontrolled epilepsy显示文摘 | Joyce A. Cramer Zhixiao J. Wang Eunice Chang Annette Powers Ronda Copher Dasha Cherepanov Michael S. Broder | 2014 | Epilepsy & Behavior2014，，： | 1 |
| 13 | SavingsBehaviour in South Asia 显示文摘 | Pradeep Agrawal Pravakar Sahoo Ranjan Kumar Dasha | 2009 | Journal of Policy Modeling2009，，31： | 1 |
| 14 | A TEM study on lithium zinc ferrite thin films and the microstructure correlation with the magnetic properties显示文摘 | Desaia M Dasha J Samajdarb I | 2001 | Journal of Magnetism and Magnetic Materials2001，231，： | 1 |
| 15 | 军事气象地理简介显示文摘2001年笔者在台湾的全球防卫杂志曾经投稿写了一篇《自然环境对军事作战的影响》,事隔八年,多收集到了不少新的资料,借用旧的前言,彻底修改结构与内容,重新写一次文章。希望看过前一版文章的读者们,不要看了前言就放弃。 | dasha | 2009 | 航空档案2009，，9： | 0 |
| 16 | 运用科技分类再利用 提升纺织废料回收率显示文摘一台分栋破旧衣物的机器正在让有用衣物避免送往垃圾填埋场有洞的袜子、虫蛀过的毛衣和被撕破的T恤……这些通常都不是人们会考虑捐赠出去的衣物。然而,英国非营利组织“救世军”(Salvation Army)正在寻求这些破旧的东西,因为它的目的是借助一台高科技机器,将衣物和其他纺织品从垃圾填埋场中拯救出来。这个组织的贸易部门在英国经营着400多家二手服装店。 | Dasha Afanasieva 竹西(译) | 2023 | 商业周刊(中文版)2023，，3： | 0 |
| 17 | 年轻人健康意识增强 非酒精烈酒正蓬勃兴起显示文摘厄瓜多尔在伦敦西北方大约一小时车程的一个实验室里,化学家马修·库尔希德(Matthew Coulshed)将一种深酒红色的液体倒人一个大塑料罐中。长凳上放着几罐迷你玫瑰花蕾、杜鹃花和其他草药,等待加工。他正在修改Sentia的原料配比。 | Dasha Afanasieva 融汐(译) | 2024 | 商业周刊(中文版)2024，，2： | 0 |
| 18 | 静谧的温暖照亮阴霾显示文摘我独处时最轻松,因为我不觉得自己乏味。即使乏味,也自己承受,不累及他人,无需感到不安。别人大概怎么都可以搪塞,自己的心灵却无法蒙混过关。每个人现在呈现的样子,都是自己过往所有经历的叠加。Dasha Pears是一个来自俄罗斯圣彼得堡的摄影师,最近在芬兰的赫尔辛基工作与生活,从事摄影已经6年了。 | Dasha Pears 本刊资料(图) | 2019 | 优雅2019，0，4： | 0 |
| 19 | 人造牛奶尝试打破仿真食品的魔咒显示文摘先是素肉,然后是实验室培育鸡肉。而今,初创公司再次押下赌注,认定无动物乳制品将成为食品技术领域的下一件大事。 | Bruce Einhorn Dasha Afanasieva 易语(译) | 2023 | 商业周刊(中文版)2023，，15： | 0 |
| 20 | 英国创意艺术学院(巴西圣保罗校区)显示文摘英国创意艺术学院(巴西)位于圣保罗的热情洋溢的Vila Madalena区,其所在建筑由Isay Weinfeld设计。该项目旨在打造一所能激发团队精神的学校,创造一个能让学生思考自我、收获灵感的空间。设计团队希望能给学生们带来惊喜,让他们沉浸在有趣的氛围中,同时让部分空间"留白",让学生们发挥创意。整座学校犹如一个巨大的操场,四周散布着抽象的体量,每一个造型简洁的体量都包含着特定的功能。 | Olga Trewas Vera Odyn Elena Kornilova Polina Litvinenko Dasha Sheina Maria Serova Julia Semkova 范嘉苑 | 2018 | 现代装饰2018，0，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员